Microperimetric changes after intravitreal bevacizumab injection for exudative age-related macular degeneration.

Abstract

PURPOSE:

To evaluate the effect of intravitreal bevacizumab on macular function in the cases of exudative age-related macular degeneration (AMD).

METHODS:

A total of 21 eyes of 21 patients with exudative AMD were included in this study. In each eye, at baseline and 1, 3 and 6 months after intravitreal bevacizumab injection, logMAR visual acuity, central 4° macular sensitivity, absolute scotoma size, fixation stability and fixation location by MP-1 microperimetry and optical coherence tomography (OCT) foveal morphologic changes were assessed. After the initial treatment phase which included three consecutive injections, the decision to re-treat was based on OCT and clinical findings. Subsequent injections could be administered at least 1 month after the previous injection period according to the OCT-guided treatment regimen.

RESULTS:

Mean retinal sensitivity within central 4° (12 points) area had increased from 3.69 ± 3.44 dB at baseline to 7.16 ± 3.27 dB at month 6. In all controls after the treatment, there was significant increase in logMAR visual acuity (p < 0.001) and MP-1 retinal sensitivity (p < 0.001). Mean absolute scotoma in test point location had decreased significantly from 12 of the 76 applied test point locations measured at baseline to five test point locations (-7 test point locations; p < 0.001) at month 6 showing statistical significance. Fixation properties had preserved in all patients 6 months after intravitreal bevacizumab treatment.

CONCLUSION:

Intravitreal bevacizumab therapy induced a significant increase in mean retinal sensitivity and significant decrease in mean absolute scotoma size during 6 months. The MP1 microperimetry proved to be a valuable tool in the evaluation of functional benefit of exudative AMD therapy with intravitreal bevacizumab.

• Authors: Hakan Ozdemir, Murat Karacorlu, Fevzi Senturk, Serra Arf Karacorlu, Omer Uysal
• Journal: Acta ophthalmologica (Acta Ophthalmol) Vol. 90 Issue 1 Pg. 71-5 (Feb 2012) ISSN: 1755-3768 [Electronic] England
• PMID: 20163371 (Publication Type: Journal Article)
• Copyright: © 2010 The Authors. Journal compilation © 2010 Acta Ophthalmol.

Chemical References

• Angiogenesis Inhibitors
• Antibodies, Monoclonal, Humanized
• VEGFA protein, human
• Vascular Endothelial Growth Factor A
• Bevacizumab

Topics

• Aged
• Angiogenesis Inhibitors (administration & dosage)
• Antibodies, Monoclonal, Humanized (administration & dosage)
• Bevacizumab
• Contrast Sensitivity (physiology)
• Exudates and Transudates
• Female
• Humans
• Intravitreal Injections
• Macular Degeneration (diagnosis, drug therapy, physiopathology)
• Male
• Middle Aged
• Retina (physiology)
• Retreatment
• Tomography, Optical Coherence
• Vascular Endothelial Growth Factor A (antagonists & inhibitors)
• Visual Acuity (physiology)
• Visual Field Tests
• Visual Fields (physiology)